Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease - 15/12/21
, Robert Terkeltaub, MD c, Michael H. Pillinger, MD d, Binita Shah, MD, MS e, Vangelis Karalis, PhD f, Eleni Karatza, PhD f, David Liew, MBBS g, h, Massimo Imazio, MD i, Jan H. Cornel, MD, PhD j, Peter L. Thompson, MBBS, MD k, Mark Nidorf, MBBS, MD lAbstract |
Over the last decade, evidence has demonstrated that long-term, low-dose colchicine (0.5 mg daily) is effective for preventing gout flare and cardiovascular (CV) events in a wide range of patients. Given the potentially expanding use of colchicine in CV disease, we here review and update the biologic effects and safety of colchicine based on recent data gathered from bench and pharmacodynamic studies, clinical reports, controlled clinical trials, and meta-analyses, integrated with important studies over the last 50 years, to offer a consensus perspective by experts from multiple specialties familiar with colchicine's long-term use. We conclude that the clinical benefits of colchicine in gout and CV disease achieved at low dose do not sustain serum levels above the upper limit of safety when used in patients without advanced renal or liver disease or when used concomitantly with most medications. Further, data accrued over the last 50 years strongly suggest that the biologic effects of long-term colchicine do not increase the risk of cancer, sepsis, cytopenia, or myotoxicity.
El texto completo de este artículo está disponible en PDF.Keywords : Colchicine, Coronary disease, Gout, Safety, Tolerance
Esquema
| Funding: None. |
|
| Conflicts of Interest: PCR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, Janssen, Novartis, UCB, Roche, Pfizer; meeting attendance support from BMS, Eli Lilly, Pfizer, and UCB Pharma and grant funding from Janssen, Novartis, Pfizer, and UCB Pharma. RT reports grant support from AstraZeneca, National Institutes of Health, and VA Research Service. MHP reports investigator-initiated research grants from Hikma Pharmaceutical and Horizon Therapeutics and serving on advisory board of Horizon Therapeutics. BS reports grant funding from the Veterans Affairs Office of Research and Development and from the National Institutes of Health National Heart Lung Blood Institute for studies on colchicine in coronary artery disease and COVID-19, which are funded to the institution and not personally, and serves on advisory board for Philips Volcano and as consultant for Terumo Medical. VK reports none. EK reports none. DL serves as a member of Pharmaceutical Benefits Advisory Committee Drug Utilization Subcommittee, Australian Government. MI currently serves on advisory board for SOBI and KINIKSA and in the past for ACARPIA. JHC reports grant funding from the Netherlands Organization for Health Research and Development (ZonMw) and the Netherlands Heart Foundation and serving on the advisory board of Amgen, AstraZeneca, and Novo Nordisk. PLT reports none. MN reports non. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
Vol 135 - N° 1
P. 32-38 - janvier 2022 Regresar al número
Artículo precedente
- Management of Orthostatic Hypotension in the Hospitalized Patient: A Narrative Review
- Amr Wahba, Cyndya A. Shibao, James A.S. Muldowney, Amanda Peltier, Ralf Habermann, Italo Biaggioni
- Geriatric Preoperative Optimization: A Review
- Kahli E. Zietlow, Serena Wong, Mitchell T. Heflin, Shelley R. McDonald, Robert Sickeler, Michael Devinney, Jeanna Blitz, Sandhya Lagoo-Deenadayalan, Miles Berger
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?